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Fig. 1 Rituximab
In the field of radiolabelled molecules, Rituximab appear as promising molecules for radiopharmaceutical
design, because it can target specifically to CD20 antigens in non-Hodgkin lymphoma.
The radiochemical purity of the labeled conjugates was
determined using SE-HPLC:
- column BioSep-SEC-s3000 (300 x7.5 mm; Phenomenex)
- flow rate 1ml/min
- isocratic elution – eluent 0.1 M phosphate buffer pH 5.8
- UV detection at 220 and 280 nm
- analysis time 20 min
- sample volume: 20μl
• Rituximab was conjugated with DTPA-, DOTA- and 1B4M -
freeze dried kit
• labelled with 177Lu used was 565 MBq (in 5 µL) per kit. the
reaction mixture was incubated at 380C for 1 hour
• 10 μl of 10 mM DTPA solution was added in 10 μl of
radiolabelled conjugate to bind non-reacted 177Lu
•HPLC analysis was performed 5 min after DTPA
addition
Fig. 2 HPLC
Results:
177Lu-Rituximab radioimunoconjugates 
with high radiolabelling yield and average 
of radiochemical purity (above 94.7%) and 
was obtained specific activity up to 
1.5GBq/mg.
Radiochromatogram of 177Lu-1B4M-Rituximab
Conslusion:
With the obtained results we can conclude that
177Lu- Rituximab radioimunoconjugates can be
used for development of the predclinical studies in
experimental animal model.
Radiochromatogram of 177Lu-DTPA-Rituximab
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